Table 1. Summary of the statistical tests performed and obtained significances.

Statistical Test
Tumor Type	Kruskal-Wallis rank sum test	Chi-square
FOLR1	p<0.0001	27.16
FPGS	p<0.0001	29.24
GGT1	p=0.0289	9.03
TYMS	p<0.0001	23.69
FOLR1/TYMS Ratio	p<0.0001	36.44
FOLR1/SLC19A1 Ratio	p<0.0001	24.94
FPGS/TYMS Ratio	p<0.0001	32.77
FPGS/GGT1 Ratio	p=0.1
ERCC1	p=0.0021	14.69
MLH1	p<0.0001	16.61
XRCC1	p=0.0131	10.75
MSH6	p=0.0064	12.29
MLH1/MSH2 Ratio	p<0.0010	16.34
	Pearson's Chi-squared test	X-squared
FOLR1/TYMS Phenotype	p<0.0001	47.34
FGPS/TYMS Phenotype	p<0.0001	47.32
MLH1/MSH2 Phenotype	p=0.0014	27.10
Grade of Differentiation	Spearman's rank correlation rho	rho
FOLR1	p<0.0001	−0.6421
FPGS	p<0.0001	−0.6501
TYMS	p<0.0001	0.6329
GGT1	p=0.0366	−0.2825
ERCC1	p<0.007	−0.3599
MLH1	p=0.0046	−0.3766
MSH6	p=0.0210	0.3105
Tumor Stage	Spearman's rank correlation rho	rho
FOLR1	p=0.0049	−0.4076
ERCC1	p=0.0147	−0.3575
MLH1	p=0.0214	−0.3383
XRCC1	p=0.0226	−0.3357
Spread to Lymph Nodes (N-Stage)	Spearman's rank correlation rho	rho
FOLR1	p=0.0001	−0.5192
FPGS	p=0.0038	−0.4021
MLH1	p=0.0111	−0.3562
Gender	Exact Wilcoxon Mann-Whitney Rank Sum Test	Z-value
FOLR1	p=0.0037	2.87
FPGS	p=0.0489	1.97
ERCC1	p=0.0408	2.04
MLH1	p=0.0308	2.15
XRCC1	p=0.0246	2.24
Overall Survival (OS)	Likelihood ratio test	Hazard Ratio
Data for 35 patients (10 events)
FOLR1	p=0.0014	1.00
FPGS	p<0.0004	1.00
TYMS	p=0.0200	0.99
ERCC1	p=0.0082	1.00
MLH1	p<0.0040	1.00
XRCC1	p=0.0263	1.00
FOLR1/TYMS Ratio	p<0.0040	1.03
FOLR1/SLC19A1 Ratio	p=0.0017	1.05
FPGS/TYMS Ratio	p<0.0001	2.54
Progression-Free Survival (PFS)	Score (logrank) test	Hazard Ratio
Data for 11 patients (8 events)
FOLR1	p=0.0049	0.99
ERCC1	p=0.0026	0.99
FOLR1/SLC19A1 Ratio	p=0.0223	0.69
FOLR1/TYMS Ratio	p=0.0200	0.26
FPGS/TYMS Ratio	p=0.0225	<0.01